Skip to main content
Ipca Laboratories Ltd. logo

Ipca Laboratories Ltd. — Investor Relations & Filings

Ticker · IPCALAB ISIN · INE571A01038 LEI · 33580069PZ8ZQVCDBC38 BSE.NS Manufacturing
Open in API
Filings indexed 724 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS IPCALAB

About Ipca Laboratories Ltd.

https://www.ipca.com

Ipca Laboratories Ltd. is a vertically integrated entity focused on the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. The company serves a global market, distributing products to over 120 countries. Its therapeutic portfolio covers rheumatology, antimalarials, cardiology, gastroenterology, pain management, and diabetology. Notably, it is a leading global producer of antimalarial agents such as Chloroquine and Hydroxychloroquine. Operations are supported by multiple manufacturing sites that adhere to international regulatory standards, alongside dedicated research and development centers. The company’s strategic emphasis on backward integration allows for optimized production processes and the delivery of high-quality medicinal solutions across diverse healthcare sectors.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 65% confidence The document is a notice filed under Regulation 30 of SEBI LODR to inform stock exchanges and the public of a scheduled conference call for Q4FY26 earnings. It contains no financial data itself and is not the earnings release nor a transcript. It is a general regulatory announcement and does not fit other specific categories, so it falls under the fallback category “Regulatory Filings.”
2026-05-21 English
Conference Call to discuss Q4FY26 Results
Regulatory Filings Classification · 85% confidence The document is an online SEBI Listing disclosure under Regulation 30(6) announcing and inviting investors and analysts to the Company's Q4 FY26 earnings conference call. It contains no financial highlights, actual earnings data, management discussion, or minutes of the call. It is not the earnings release (ER), transcript (CT), investor presentation (IP), or any detailed report. It is a standard regulatory announcement of an upcoming event and thus fits into the general Regulatory Filings fallback category (RNS).
2026-05-21 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2026-04-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-08 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper notice about the re-lodgement transfer request of physical shares. It references compliance with SEBI regulations and includes a newspaper notice as an enclosure. The content is primarily an announcement of a corporate action related to share transfer procedures, not a financial report, earnings release, or management discussion. It does not contain financial statements, audit information, or detailed management commentary. The document is also not a proxy solicitation, voting results, or a remuneration report. Given the nature of the content as a regulatory announcement about share transfer notices and related procedural information, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-02 English
Trading Window
Regulatory Filings
2026-03-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.